USP <601>
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders.
AccreditedStandards
Aerodynamic Particle Size TestingUSP <601>USP <1601>FDA MDI / DPI
Standards for NGI and Andersen impactor APSD studies of inhalers, nebulizers, and nasal products.
Use this cluster to connect particle-size evidence with compendial method choices, FDA quality expectations, recovery controls, assay outputs, and reportable APSD metrics.
Standard roster
Individual standards in this cluster
USP <601>, USP <1601>, and FDA MDI / DPI guidance form the citation set; ARE Labs translates them into APSD setup, run controls, QA records, and report outputs.
USP <1601>
USP <1601> applies when nebulized products need characterization of delivery rate, total delivered drug, and aerodynamic aerosol assessment.
AlignedFDA MDI / DPI
FDA MDI / DPI quality guidance links APSD results to formulation controls, device performance, batch comparison, and CMC documentation.
AlignedPurpose & when to use
Aerodynamic Particle Size Distribution (APSD) testing uses cascade impactors to separate inhaled aerosol mass by aerodynamic cut point. This standards cluster covers USP <601>, USP <1601>, and FDA MDI / DPI quality guidance. It helps teams plan how those references apply to NGI or Andersen impactor studies for inhalers, nebulizers, and related nasal products:
- MDI and DPI teams use USP <601> and FDA guidance when APSD, delivered dose, and fine-particle dose need one reviewable package.
- Nebulizer programs use USP <1601> when aerosol output, delivery rate, delivered drug, and aerodynamic assessment must share one method plan.
- Formulation or device changes use FDA quality expectations to compare APSD profiles, stage recovery, assay readiness, and batch-to-batch behavior.
- Investigations use USP <601> framing to separate device handling, flow control, stage recovery, extraction, and analytical contributors.
Use this cluster when you need to trace APSD evidence from device setup through recovery and assay to the final report, with deviations documented as part of the basis for interpreting the results.
Applicable to
Built around inhalation product decisions
The cluster applies when emitted aerosol performance depends on device handling, flow control, impactor recovery, and assay-ready collection across inhaled or nasal drug-delivery formats.
Standards in this group
What each citation controls
This page is a cluster, not three separate standard summaries. USP chapters define compendial performance or characterization frames, while FDA guidance sets quality expectations for development and manufacturing information. The summaries below stay at applicability level: what each citation controls, how it affects ARE Labs study design, and what source was verified.
USP
AccreditedUSP <601>
Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders - Performance Quality Tests
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders. On APSD studies, it informs device setup, dose-delivery context, stage recovery, extraction readiness, and report language for MMAD, GSD, fine-particle dose, and related performance outputs.
USP official preview page verified from the official publisher on 2026-05-17.
USP
AlignedUSP <1601>
Products for Nebulization - Characterization Tests
USP <1601> applies when nebulized products need characterization of delivery rate, total delivered drug, and aerodynamic aerosol assessment. ARE Labs maps that frame to jet, mesh, ultrasonic, or investigational nebulizer setups with controlled operation, recovery timing, and assay-ready collection.
USP official preview page verified from the official publisher on 2026-05-17.
FDA
AlignedFDA MDI / DPI
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - Quality Considerations
FDA MDI / DPI quality guidance links APSD results to formulation controls, device performance, batch comparison, and CMC documentation. ARE Labs uses it to connect impactor data with delivered dose, shot-weight checks, flow verification, assay readiness, and documented deviations.
FDA draft guidance page verified from the official publisher on 2026-05-17.
Accredited where held, aligned where followed
This page separates formal accreditation from standards alignment. ARE Labs can cite accredited USP <601> scope where applicable; USP <1601> and FDA MDI / DPI guidance are treated as aligned frameworks unless a separate scope is confirmed.
- USP <601>AccreditedAccredited APSD performance frame where scope applies.
- USP <1601>AlignedNebulizer characterization frame followed by protocol.
- FDA MDI / DPIAlignedQuality guidance translated into study and reporting controls.
Operational chain
How ARE Labs turns the standards into a study
The standards set the study frame, but the final APSD method still has to match the product, formulation, assay, and regulatory objective. ARE Labs translates USP and FDA expectations into setup, operation, recovery, adaptation, and reporting decisions.
01
Configuration
Select the impactor path
We map USP <601>, USP <1601>, or FDA MDI / DPI expectations to the NGI or ACI setup, flow condition, actuation approach, and collection strategy.
Protocol setup02
Operation
Control the aerosol run
Flow verification, leak checks, stage condition, device handling, and recovery timing are recorded so the USP or FDA frame is visible in the bench workflow.
Traceable run record03
Adaptation
Document fit-for-purpose choices
When no single standard governs the exact device or formulation, ARE Labs records the adaptation rationale while keeping USP <601>, USP <1601>, or FDA boundaries explicit.
Rationale log04
Reporting
Connect data to reviewable evidence
Reports connect APSD, MMAD, GSD, fine-particle metrics, recovery, deviations, limitations, and assay outputs back to USP and FDA expectations.
Review-ready reportData quality, QA/QC & documentation
For APSD studies, reviewers need clear records showing how each result was produced. ARE Labs connects USP and FDA study framing to traceable setup checks and run controls. The records also cover recovery notes, assay readiness, raw data retention, and documented deviations.
Connect setup to citation
USP <601> and USP <1601> runs link device setup, impactor configuration, flow checks, and collection timing to the selected study frame.
Preserve bench conditions
FDA MDI / DPI expectations make actuation handling, recovery timing, leak checks, and assay readiness part of the review trail.
Retain raw and reduced data
USP <601> APSD files retain stage mass, MMAD, GSD, fine-particle metrics, calculations, and calibration references for review.
Document method decisions
When a device does not map cleanly to USP or FDA language, ARE Labs records the rationale, limitation, and interpretation impact.
Separate scope from alignment
ISO 17025 review language distinguishes accredited USP <601> work from aligned USP <1601> or FDA guidance followed by protocol.
Why ARE Labs
ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.
Reviewed byJamie Balarashti - Weston Schaper
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported
Common questions
The questions below address how inhalation, formulation, and quality teams plan APSD work under USP <601>, USP <1601>, FDA MDI / DPI guidance, or a blended study plan. They cover the practical decisions ARE Labs resolves when scoping a study, before protocol drafting, sample planning, and reporting begin.
Q. Which impactor path applies?
A. NGI is often preferred for modern inhalation characterization. ACI remains useful for legacy methods, comparability work, and established submissions. ARE Labs selects the method based on product history, acceptance criteria, and review expectations.
Q. Does FDA guidance replace USP testing?
A. No. FDA guidance describes development and manufacturing quality expectations, while USP chapters often provide the compendial test structure. A study can cite both when both are needed for method design and reporting.
Q. What does aligned mean here?
A. Aligned means ARE Labs follows the standard or guidance by protocol where applicable, but does not claim formal accreditation unless the citation is in the accredited scope.
Q. How are paywalled standards handled?
A. ARE Labs links only to official publisher or regulator sources. When full text is paywalled, the page summarizes applicability and lab implementation without reproducing protected method text.
Q. What is included in the report?
A. Report contents depend on the protocol. They can include setup and calibration records, stage mass, MMAD, GSD, fine-particle dose, recovery, assay outputs, raw data references, deviations, and QA review.
Related services & devices
Related services & devices
Service
Particle Size Distribution (PSD) Testing
Primary service route for NGI, Andersen, real-time sizing, recovery, and cascade impactor reporting.Read more ->ServiceDose Uniformity & Emitted Dose
Pairs emitted-dose evidence with APSD for inhalation product performance packages.Read more ->ServiceSpray Pattern & Plume Geometry
Adds spray-shape and plume evidence for nasal products and actuation studies.Read more ->ServiceBreathing Simulation
Connects emitted aerosol performance to inhalation profiles and patient-use flow conditions.Read more ->DevicesMetered Dose Inhalers
Pressurized inhaler devices where APSD, delivered dose, and actuation handling often converge.Read more ->DevicesDry Powder Inhalers
Flow-dependent inhaler devices that use APSD to characterize powder emission behavior.Read more ->DevicesNebulizers
Jet, mesh, ultrasonic, and related nebulizer systems tied to USP <1601> characterization.Read more ->DevicesNasal Drug Spray Devices
Nasal formats where APSD may sit beside plume, spray pattern, and dose evidence.Read more ->Related clusters
Related standards clusters
APSD overlaps with neighboring inhalation clusters. These routes help teams move from cascade-impactor sizing into dose, nebulizer performance, spray imaging, or breathing-profile questions without losing the standards context.
Standards